In Depth Featured article Pharma’s path to Net Zero: Targeting Scope 3 emissions Also in this section Profit vs inquiry: Clash of objectives in academic and commercial trials CTO Europe 2023: A snapshot of challenges and opportunities in oncology The future of cell and gene therapy manufacturing VPAS is dead, long live VPAG Q&A: European Pharmaceutical legislation: hindrance or help? 02/23/2024 23:27:04